Prognostic factors in multiple myeloma

Hematol Oncol Clin North Am. 1999 Dec;13(6):1295-314, xi. doi: 10.1016/s0889-8588(05)70128-3.


There is significant variation in the survival of patients with myeloma. This article reviews the major prognostic factors in myeloma and the evidence supporting their usefulness in clinical practice and research. The factors reviewed include serum beta 2-microglobulin, bone marrow plasma cell labeling index, cytogenetics, plasmablastic morphology, and other standard clinical laboratory variables. Novel factors such as bone marrow angiogenesis are also discussed. A combination of independent factors provides greater prognostic information than any one factor alone, and survival data using various combinations of prognostic factors are presented.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Aging
  • Chromosome Aberrations
  • Humans
  • Multiple Myeloma* / genetics
  • Multiple Myeloma* / mortality
  • Multiple Myeloma* / pathology
  • Multiple Myeloma* / therapy
  • Plasma Cells / pathology
  • Prognosis
  • Survival Rate